Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Assessment of the Calcimimetic Agent AMG 073 for the Treatment of Subjects With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism.

NCT00037518 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00037518
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00037518 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Assessment of the Calcimimetic Agent AMG 073 for the Treatment of Subjects With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism.
Lead sponsor
Amgen
Phase
Phase 4
Overall status
Completed
Start date
April 30, 2001
Completion date
Not reported
Enrollment
46
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hyperparathyroidism, parathyroid neoplasms